Abstract
The bioavailability of a new sustained-release potassium chloride (KC1) tablet, designed for once-a-day dosing, was compared to a KC1 elixir using urinary excretion data. The study utilized 25 male volunteers dosed in a crossover design in a dietary/activity-controlled environment. The regimens consisted of a total of 80 mEq of potassium in three equally divided doses of elixir every 6 hr and a single 80-mEq dose using four 20-mEq sustained-release (SR) tablets. The mean time to maximum rate of potassium urinary excretion was 2.2 hr for the first elixir dose and 5.5 hr after the SR tablet (P < 0.01), thereby supporting the prolonged-release properties of this formulation. After correction for baseline urinary potassium excretion, the mean total 24-hr urinary potassium excretion was 42.18 mEq for the elixir and 40.41 mEq for the SR tablet. The results indicate that the absorption pattern from the SR tablet is equal to three doses of KC1 elixir dosed 6 hr apart.
Similar content being viewed by others
REFERENCES
J. Arnold, J. T. Jacob, and B. Riley. J Pharm Sci 69:1416–1481 (1980).
M. Gibaldi and D. Perrier. In Pharmacokinetics, 2nd ed. Marcel Dekker, New York, 1982, pp. 180–184.
J. Baver, G. Toro, and P. Ackerman. Bray's Clinical Laboratory Methods. C. V. Mosby, St. Louis, Mo., 1962, pp. 68–69.
W. White and S. Frankel. Chemistry for Medical Technology, 2nd ed., C. V. Mosby, St. Louis, Mo., 1965, pp. 124–125.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Betlach, C.J., Arnold, J.D., Frost, R.W. et al. Bioavailability and Pharmacokinetics of a New Sustained-Release Potassium Chloride Tablet. Pharm Res 4, 409–411 (1987). https://doi.org/10.1023/A:1016438413297
Issue Date:
DOI: https://doi.org/10.1023/A:1016438413297